Stomach Cancer Treatment
Stomach Cancer Treatment
Treatment follows the stage, and within each stage it follows the molecular profile: endoscopic resection for disease confined to the lining, gastrectomy with lymph-node dissection for localised disease, and drug therapy selected by HER2, PD-L1 and MSI for advanced disease.
Treatment by stage, in one table
| Stage | Standard approach | What decides the details |
|---|---|---|
| Very early (confined to the mucosa or superficial submucosa) | Endoscopic resection — EMR or ESD | Depth, size, ulceration and differentiation, measured on the resected specimen |
| Stage I | Surgery — subtotal or total gastrectomy with lymph-node dissection | Tumour location; whether adjuvant therapy is added |
| Stage II–III | Drug therapy before surgery, gastrectomy with D2 dissection, drug therapy after | Response to preoperative therapy; molecular markers |
| Stage IV | Systemic therapy as the mainstay | HER2, PD-L1, MSI status; symptoms and organ function |
Two principles run through all of it. First, the stage is provisional until it is complete — a stage assigned without endoscopic ultrasound and laparoscopy is a guess dressed as a number. Second, the molecular report is not a later refinement: it belongs in the first treatment decision, because for advanced disease it picks the first regimen rather than the third.
Endoscopic resection: removing the cancer and keeping the stomach
For a cancer confined to the innermost layer of the stomach wall, the tumour can be lifted off the muscle and removed through an endoscope. Endoscopic mucosal resection (EMR) lifts and snares smaller lesions; endoscopic submucosal dissection (ESD) dissects a larger lesion off the muscle layer in one piece, which matters because the pathologist needs the whole specimen to judge whether the resection is complete.
The advantage is not cosmetic. Keeping the stomach means keeping normal eating, normal weight and normal long-term nutrition — which for a condition diagnosed at a curable stage is a quality-of-life decision as much as an oncological one. The discipline is strict: the resection is appropriate only when the tumour meets defined criteria on depth, size, ulceration and differentiation, and these are judged on the specimen after removal, not before.
When the specimen shows the tumour has gone deeper than expected, or the margin is involved, the recommendation moves to surgery. That is not a failure of the endoscopic route; it is the reason the criteria exist. Patients should ask, in advance, what happens if the specimen shows more than expected — a centre that does ESD will have a clear answer.
Gastrectomy: what the operation involves
A gastrectomy removes the tumour with an adequate margin and the lymph nodes that drain the region. Subtotal gastrectomy removes the distal part of the stomach and reconnects the small bowel to the remnant; total gastrectomy removes the whole stomach and reconnects the oesophagus to the small bowel, usually with a pouch to slow transit. The choice depends on where the tumour is and how much healthy stomach can be left.
The lymph-node dissection is the technical heart of the operation. D2 dissection — the removal of the second echelon of lymph-node stations — is the standard in East Asia, where gastric cancer surgery is performed at volume, and it is associated with better survival in locally advanced disease than a more limited dissection. It is also technically demanding, which is why the surgeon's case volume in gastrectomy is a reasonable question to ask.
- Laparoscopic gastrectomy — through several small incisions; less blood loss, earlier recovery of bowel function and a shorter stay, with oncological outcomes equivalent to open surgery in the settings where it is established.
- Robot-assisted gastrectomy — adds magnified three-dimensional vision and instruments that hold still without tremor, which is useful in the fine dissection around major vessels that a D2 dissection requires.
- Open surgery — remains the right choice for some extensive or reoperative cases, and is not a lesser option simply because it is older.
At our hospitals the approach is chosen per patient: Foshan Fosun Chancheng Hospital, the network's Grade III-A flagship, operates with the da Vinci surgical system and CyberKnife M6 radiosurgery, and gastric resection is planned within the gastrointestinal multidisciplinary team rather than by a single specialty.
Radiotherapy: where it has a role, and where it does not
Gastric cancer is less radio-sensitive than many tumours, and radiotherapy is not part of every treatment plan. It is used for specific purposes: where a tumour cannot be removed completely, where an inoperable tumour is causing symptoms such as bleeding or obstruction, or in selected adjuvant settings where the surgical margins or nodal status leave residual risk. It is also used for painful bone or nodal metastases, where a short course can restore function.
Two delivery options change what radiotherapy can do here. Intensity-modulated radiotherapy shapes the dose around the stomach and the nodes while sparing the kidneys, liver and spinal cord — which matters in the upper abdomen, where those organs sit close to the target. CyberKnife radiosurgery tracks the target with sub-millimetre accuracy and delivers treatment in a small number of outpatient sessions rather than weeks of daily fractions, which is useful for a defined recurrence or a small residual lesion rather than for large fields.
Drug therapy: what the molecular report buys you
Chemotherapy uses platinum and fluoropyrimidine drugs, and it appears at three different points in the disease: before surgery to shrink a locally advanced tumour and test its biology, after surgery to reduce the risk of recurrence, and as the main treatment in advanced disease. The same drug families, three different jobs.
Beyond chemotherapy, drug choice follows the markers described on the diagnosis page:
- HER2-positive — trastuzumab is added to first-line chemotherapy for advanced disease.
- PD-L1 positive — an anti-PD-1 immunotherapy is added to first-line treatment, where the score and the setting support it.
- MSI-H or dMMR — immunotherapy can be used, and in later lines it may be the most active option remaining.
- Later lines — anti-angiogenic therapy such as apatinib is used in previously treated advanced disease in China; agents against CLDN18.2 are available in some countries and in trials in China.
Drug access is the practical reason patients travel. Agents that are approved in one country and not another, or available only in a trial, are frequently the deciding variable in advanced gastric cancer — and our centres can tell you, from your molecular report, which of these you are a candidate for before you travel, at a drug cost typically 30–50% of the equivalent treatment in Europe or the US.
Nutrition: the part of treatment that decides how the rest goes
After stomach surgery, eating is the main thing that changes, and it is the thing patients most want to be prepared for. After a subtotal gastrectomy the stomach is smaller and empties faster; after a total gastrectomy there is no reservoir at all, and the small bowel takes over. Both require eating little and often, separating fluids from solids at first, and supplementing vitamins — particularly B12, which can no longer be absorbed without a stomach.
This is not discharge advice; it is part of the treatment plan. Patients who are well nourished before surgery tolerate it better and recover faster, and those who arrive already depleted are supported first — sometimes with a period of nutritional support before an operation rather than after it. Our centres include clinical nutrition in the multidisciplinary review for exactly this reason, and the dietary plan is written down before discharge so it can be followed at home.
How the decision is actually made
Stomach cancer sits at the meeting point of four specialties, and the sequence matters: gastroenterology and surgery define what is resectable, medical oncology defines the drug strategy around the operation, radiation oncology defines where radiotherapy adds something, and clinical nutrition makes the plan survivable in practice. Reviewed separately, these four produce four opinions; reviewed together, they produce one.
Our multidisciplinary team reviews the complete file — endoscopy, pathology, imaging and molecular results — and returns a written plan. Send complete records and the assessment is returned within 48 hours, including whether endoscopic resection is a realistic option for you and which drug strategy your molecular profile supports.